Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study

Journal of Thoracic Oncology(2024)10.1016/j.jtho.2024.01.012Source: DataRank Database

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study is a research paper published in Journal of Thoracic Oncology (2024). On theSindex it has a DataRank of 0.571. It has been cited 44 times.

N/A

0.571DataRank · unranked

Scored on demand from live citation data

Open Access44 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 12.62)OA: bronzeTopics (42)IDs (PubMed, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.571

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (57)

So Yeon Kim ORCID,Jacqueline V. Aredo ORCID,Jamie Feng ORCID,Frances A. Shepherd ORCID,Chao Xu ORCID

Live enrichment

PubMed:38278303 OpenAlex:https://openalex.org/W4391180278

NIA NIH HHS

Grant: P30 AG015272

NCI NIH HHS

Grant: P30 CA062203

NCI NIH HHS

Grant: U54 CA242646

FWCI

12.62

Citation Percentile

1.0%

Citation Trend

2024

2025

2026

bronzeLicense: http://www.elsevier.com/open-access/userlicense/1.0/

journalhttp://www.jto.org/article/S1556086424000327/pdf

publisherhttp://www.jto.org/article/S1556086424000327/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1556086424000327?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1556086424000327?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtho.2024.01.012

Fields of Study

Lung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesRadiomics and Machine Learning in Medical Imaging

MeSH Terms

AcrylamidesAgedAniline CompoundsAntibodies, MonoclonalCarcinoma, Non-Small-Cell LungFemaleHumansIndolesLung NeoplasmsMaleMiddle AgedMutationPyrimidinesRetrospective StudiesChemoradiotherapyConsolidation ChemotherapyErbB Receptors

Keywords

DurvalumabMedicineOsimertinibCommon Terminology Criteria for Adverse EventsRetrospective cohort studyClinical endpointInternal medicineOncologyProportional hazards modelHazard ratioCohortAdverse effectConfidence intervalAdenocarcinomaCancerRandomized controlled trialNivolumabEGFRChemotherapyTargeted TherapyAdverse EventsNon–small Cell Lung Cancer